9 November 2022
Biorelate and Copyright Clearance Centre announce strategic integration
Manchester, UK. Biorelate Limited (“Biorelate”) and CCC (Copyright Clearance Center), have announced a strategic integration. Biorelate’s customers will immediately have the option to access subscription-only scholarly article content in XML format licensed...
8 November 2022
First Choice Neurology partners with Cytox
November 7, 2022 – First Choice Neurology (FCN), the largest neurology group in the U.S. with more than 41 facilities in six Florida counties and services at 35 major hospitals, has partnered with U.K-based Cytox to become the first practice in the United States to offer...
3 October 2022
Oxford BioTherapeutics enters into Commercial License Agreement with Genmab
• OBT licenses to Genmab the rights to a novel, pre-clinical first-in-class immuno-oncology (IO) antibody. • Under its Commercial License Agreement with OBT, Genmab will obtain the exclusive right to develop and commercialize novel antibody therapeutics utilizing...
28 September 2022
“Gift of time” could enable nearly 100 more kidney transplants each year
• Kidney Research UK says that a new method of preserving donated kidneys could offer hope and the “gift of time” to save kidneys from being discarded … • The charity reveals that nearly 100 kidneys a year are not transplanted after retrieval as they are deemed...
8 September 2022
Breakthrough in identifying risk of renal impairment in people with diabetes
Research published in the Future of Healthcare Journal shows that models developed by UK healthtech start-up Gendius can determine which patients with type 2 diabetes are most likely to have renal impairment, allowing healthcare systems to prioritise the highest risk patients...
8 August 2022
INFEX Therapeutics awarded Biomedical Catalyst grant for COV-X project
Alderley Park, Cheshire, U.K – Infex Therapeutics, a leading anti-infectives specialist, is delighted to announce a successful grant award of £850,000 to support its 18 month, £1m COV-X project, titled: “Optimisation of a novel series of SARS-CoV-2...
3 August 2022
Monument Therapeutics presents positive preclinical data for cognitive impairment in schizophrenia programme
Manchester, UK, August 02, 2022: Monument Therapeutics, a stratified medicine company, announced at the British Association for Psychopharmacology conference, positive preclinical results supporting the use of their proprietary non-invasive digital biomarker and drug MT1988 to...
2 August 2022
MicroBioSensor launches QUICKCHECK™ designed in partnership with Smallfry
A device that can help speed the diagnosis of peritonitis in vulnerable kidney and liver failure patients. With results 10,000x faster than current methods, this portable and rapid detection device now means that nurses can carry out an instant leukocyte count at the...
11 July 2022
iiCON to expand pipeline following Research England funding boost
The outstanding results being achieved by the Infection Innovation Consortium – iiCON – have been acknowledged today, with £1.7 million of additional funding from Research England confirmed. Led by Liverpool School of Tropical Medicine, the iiCON consortium...
15 June 2022
Monument Therapeutics announces the start of its first clinical study for novel treatment for neuroinflammation
Manchester, UK, June 13, 2022: Monument Therapeutics, a stratified medicine company, today announced that their first-in-human Phase I study of MT1980, a novel formulation of an on-market anti-inflammatory compound, has commenced. MT1980 has been specifically created as a novel...